Jefferies raises Nektar Therapeutics price target on alopecia data By Investing.com

Jefferies raised its price target on Nektar Therapeutics to $150 from $121 and kept a Buy rating, citing stronger-than-expected Rezpeg Phase 2 alopecia areata data and lifting its success probability to 55% from 20%. The firm now sees about $1.3 billion in peak U.S. adjusted sales for the indication and expects upcoming catalysts in Q2, June/July, and Q4. The article also notes recent equity offerings totaling $575 million potential proceeds, which help fund development but add some dilution risk.

Analysis

The market is starting to re-rate NKTR from a binary biotech to a platform story with multiple shots on goal, but the near-term tape is still dominated by financing overhang. The biggest second-order effect is that every positive clinical read now lowers the cost of capital for the company’s broader pipeline, which means the equity story can keep expanding even if alopecia is only the first commercial anchor. That said, repeated equity issuance after a 9x+ run is a classic signal that management is monetizing strength into future dilution, so the stock may become more sensitive to any hint that data quality or dosing convenience is less differentiated than bulls assume.

The competitive implication is broader than JAKs: if Rezpeg really proves “broad first-line” use, it can pressure the entire dermatology treatment ladder by forcing payers to justify step edits and prior auth around older oral agents. That would most likely hit the share of wallet for incumbents with weaker safety narratives rather than just one direct competitor, because dermatologists tend to cluster around operational simplicity and tolerability once efficacy clears a threshold. The second-order winner could be specialty pharmacy and infusion/distribution channels if uptake is broad, but only if dosing cadence and persistence stay clean in real-world use.

The main risk is timeline slippage. The stock is now trading on a sequence of catalysts over the next 3-9 months, so any delay in the end-of-phase-2 meeting, weaker off-treatment durability, or a less compelling Phase 3 setup could compress the multiple quickly. At this valuation, the market is paying for a smooth regulatory path and expanding label optionality; if the data merely confirm rather than improve, the stock can de-rate even without a fundamental failure.

Contrarian view: the move may be over-extended versus what the next catalyst actually de-risks. The current setup resembles a ‘good drug, expensive stock’ transition where upside requires both clinical validation and disciplined capital allocation, but the recent financings suggest management is prioritizing runway over per-share accretion. In that regime, the best risk/reward may be to own volatility rather than chase the common stock outright.

Key Decisions for Investors

• Maintain a tactical long NKTR only into catalysts, but size it as a volatility trade rather than a core biotech position; use a 4-8 week horizon into the end-of-phase-2 meeting with a tight downside stop if sentiment turns on financing/delay risk.
• Prefer call spreads over stock for NKTR into the next 1-2 catalysts: upside remains meaningful if the market extends the alopecia probability jump, but repeated equity issuance caps per-share upside and makes defined-risk structures superior.
• If already long NKTR, trim into strength and pair the residual position against a basket of higher-quality, less dilution-prone specialty biotech names to isolate event alpha from financing beta.
• Watch for a post-financing pullback to add only if volume normalizes and the stock holds above the recent offering range; that would suggest the market is willing to absorb dilution and still price in pipeline optionality.
• For event-driven desks, consider a short-dated strangle/straddle around the next data readout if implied volatility lags catalyst risk; the stock has enough history and headline sensitivity to justify owning realized volatility rather than directional exposure.